drugset
drugset / Trial / NCT02440633

A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects

NCT02440633 ↗

Phase 1 Completed 8 enrolled Otsuka Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To obtain absorption, metabolism and excretion data for parent drug and any metabolites.

Timeline

Start
2015-05
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject 14C-OPS-2071 Unknown 50 mg Oral

Indications

enteritis